An oral Wnt-pathway blocking candidate combined with lenvatinib showed durable tumor shrinkage in women with advanced endometrial cancer after immunotherapy failed. The results, published in EClinicalMedicine from the dose-expansion phase of a global study, reported promising efficacy and sustained responses in a difficult-to-treat post–immunotherapy population. The experimental approach targets a molecular “switch” inside tumor cells, aiming to improve outcomes when checkpoint-based strategies no longer control disease. Because the cohort had already progressed through multiple lines, the durability signals clinicians will watch closely for response durability and subsequent disease-control endpoints. For trial design, the key follow-up will be how this combination performs across biomarker-defined subgroups and whether it can convert response into longer progression-free survival in later-stage studies or randomized trials.